MSX.AU Miro Sciences Ltd
- Market cap
- AUD 19.5M
- P/E
- -
- P/B
- 1.32x
- ROE
- -31.7%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is MSX.AU undervalued?
Graham numberThe Graham number of Miro Sciences Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Miro Sciences Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-31.7%), below 10%.
ROA 1/1
Return on assets (-30.9%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-117.0%) is below the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.9 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.3x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Miro Sciences Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Miro Sciences Ltd
Miro Sciences Ltd engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. Miro Sciences Ltd was formerly known NeuroScientific Biopharmaceuticals Limited and change its name to Miro Sciences Ltd in…
Full company profileMiro Sciences Ltd financial statements
Miro Sciences Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Income Statement | ||||
| Operating Income | -6.12M | -2.06M | -2.01M | -5.11M |
| EBITDA | -1.01M | 426K | -1.75M | -3.31M |
| Net Income | -1.07M | 324K | -1.85M | -4.69M |
| EPS | -0.01 | 0.00 | -0.01 | -0.01 |
| Balance Sheet | ||||
| Total Assets | 5.29M | 9.69M | 17.0M | 15.2M |
| Total Liabilities | 597K | 85.7K | 149K | 375K |
| Shareholders' Equity | 4.69M | 5.35M | 16.8M | 14.8M |
| Cash & Short-term Investments | 4.91M | 9.20M | 7.27M | 2.63M |
| Cash Flow | ||||
| Capital Expenditure | 0.00 | 1.82K | 0.00 | 0.00 |
| Free Cash Flow | -2.30M | 42.4K | -941K | -2.78M |
| Ratios | ||||
| ROE | -22.8% | 6.1% | -11.0% | -31.7% |
| ROA | -20.2% | 3.3% | -10.9% | -30.9% |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Miro Sciences Ltd dividends
Miro Sciences Ltd has not paid dividends in the last 4 fiscal years.
Who owns Miro Sciences Ltd
- Insiders 45.21%
- Institutions 0.00%
- Public & others 54.79%
- Shares outstanding 390M
- Free float 153M
Miro Sciences Ltd company profile
- Company name
- Miro Sciences Ltd
- Ticker
- MSX.AU
- ISIN
- AU0000496887
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Level 4, Perth, WA, Australia, 6000
- Phone
- 61 8 6268 2641
- Website
- neuroscientific.com
About Miro Sciences Ltd
Miro Sciences Ltd engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. Miro Sciences Ltd was formerly known NeuroScientific Biopharmaceuticals Limited and change its name to Miro Sciences Ltd in October 2026. The company was incorporated in 2002 and is based in Perth, Australia.
Miro Sciences Ltd management
3- Mr. Nathan SmithChief Executive Officer
- Dr. Marian SturmChief Scientific Officer
- Dr. Catherine Cole MBBSChief Medical Officer